SYNCOMF Stock Overview
Manufactures, markets, and sells pharmaceutical formulation products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SYNCOMF from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Syncom Formulations (India) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹18.12 |
| 52 Week High | ₹27.90 |
| 52 Week Low | ₹10.95 |
| Beta | 1.63 |
| 1 Month Change | -10.16% |
| 3 Month Change | -4.68% |
| 1 Year Change | 17.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 123.70% |
Recent News & Updates
Does Syncom Formulations (India) (NSE:SYNCOMF) Have A Healthy Balance Sheet?
Jan 11
Getting In Cheap On Syncom Formulations (India) Limited (NSE:SYNCOMF) Is Unlikely
Dec 10Recent updates
Does Syncom Formulations (India) (NSE:SYNCOMF) Have A Healthy Balance Sheet?
Jan 11Getting In Cheap On Syncom Formulations (India) Limited (NSE:SYNCOMF) Is Unlikely
Dec 10Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Aug 30Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Jul 16Some Syncom Formulations (India) Limited (NSE:SYNCOMF) Shareholders Look For Exit As Shares Take 28% Pounding
Mar 21Syncom Formulations (India) Limited's (NSE:SYNCOMF) 27% Price Boost Is Out Of Tune With Earnings
Dec 29Syncom Formulations (India) Limited's (NSE:SYNCOMF) Shares Climb 26% But Its Business Is Yet to Catch Up
Dec 27Shareholder Returns
| SYNCOMF | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.1% | 0.1% | -0.6% |
| 1Y | 17.7% | 24.0% | 9.8% |
Return vs Industry: SYNCOMF underperformed the Indian Pharmaceuticals industry which returned 24.9% over the past year.
Return vs Market: SYNCOMF exceeded the Indian Market which returned 12% over the past year.
Price Volatility
| SYNCOMF volatility | |
|---|---|
| SYNCOMF Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 8.9% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: SYNCOMF has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: SYNCOMF's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 998 | Vijay Bankda | www.syncomformulations.com |
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It operates through Manufacturing and Dealing in Pharmaceutical Drug & Formulations, Trading of Commodities, and Renting of Properties segments. The company offers antibiotics/antiinfectives, anthelmintics, antimalarial, cardiac, derma, gastro, gynae, opthal, ortho, and pediatrics formulations.
Syncom Formulations (India) Limited Fundamentals Summary
| SYNCOMF fundamental statistics | |
|---|---|
| Market cap | ₹17.07b |
| Earnings (TTM) | ₹331.45m |
| Revenue (TTM) | ₹3.28b |
51.5x
P/E Ratio5.2x
P/S RatioIs SYNCOMF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SYNCOMF income statement (TTM) | |
|---|---|
| Revenue | ₹3.28b |
| Cost of Revenue | ₹2.04b |
| Gross Profit | ₹1.25b |
| Other Expenses | ₹915.54m |
| Earnings | ₹331.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.35 |
| Gross Margin | 37.98% |
| Net Profit Margin | 10.10% |
| Debt/Equity Ratio | 4.5% |
How did SYNCOMF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/22 04:59 |
| End of Day Share Price | 2025/01/22 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Syncom Formulations (India) Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|